Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Semaglutide Implant (NPM-139)
Semaglutide · 1 trial · 1 indication
total semaglutide concentration
Maximal semaglutide concentration
Time to reach maximal semaglutide concentration
Incidence of treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| Semaglutide Implant (NPM-139) | EXPERIMENTAL | Each participants in this arm will receive one Semaglutide Implant (NPM-139) which will be inserted subcutaneously in the upper outer arm and subsequently removed after 4 weeks of treatment. |
| Semaglutide (Wegovy) weekly injection | ACTIVE_COMPARATOR | Each participant in this arm will receive Semaglutide (Wegovy) 0.25 mg subcutaneous injection weekly for 4 weeks of treatment. |
| Name | Type | Description |
|---|---|---|
| Semaglutide Implant (NPM-139) | COMBINATION_PRODUCT | Semaglutide Implant (NPM-139) is a drug/device combination product consisting of a subdermal titanium implant \~23 mm long and 2 mm in diameter, containing a sterile liquid formulation of semaglutide that is released from the implant at a substantially constant rate over at least 15 weeks. |
| Semaglutide (Wegovy) weekly injection | DRUG | Semaglutide (Wegovy) is a clear, colorless solution provided as Wegovy FlexTouch four-dose pens: 0.25 mg/0.5 mL. It is injected SC in the abdomen, thigh or upper arm once/week. |
Inclusion Criteria: * BMI between 27 and 40 kg/m2 (inclusive) * HbA1c \</= 6.0% and FPG \</+ 6.7 mmil/L * eGFR \>/= 60 mL/m2 * No significant health issues in the opinion of the Investigator that would preclude study participation, as determined by medical history and physical examination Exclusio...
Semaglutide is being developed for the treatment of Obesity and Overweight. It is an investigational drug currently in Phase 1 clinical development. The drug is being studied as a subcutaneous implant formulation, which is designed to provide a long-acting approach to weight management.
Semaglutide targets the GLP1 receptor (GLP1R) and acts as an agonist. By activating this receptor, it mimics the action of the naturally occurring glucagon-like peptide-1 hormone, which plays a role in regulating appetite and food intake.
Semaglutide is being developed by Vivani Medical, Inc., a company listed on the stock exchange under the ticker symbol VANI. The company is advancing this drug as a subcutaneous implant for the treatment of obesity and overweight.
Semaglutide is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is designed to evaluate its safety, tolerability, and pharmacokinetics.
Semaglutide is being studied in one Phase 1 clinical trial with the identifier NCT07430059. This trial is titled 'Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant' and is expected to enroll 20 participants with Obesity and Overweight. The trial is not yet recruiting.
Yes, Semaglutide is also known as Semaglutide Implant (NPM-139). This alternative name refers to the specific implant formulation being developed by Vivani Medical. The drug is being studied as a subcutaneous implant for the treatment of obesity and overweight.